Patents by Inventor Brendan M. Giles

Brendan M. Giles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10865228
    Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 15, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Publication number: 20200330584
    Abstract: The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Application
    Filed: July 8, 2020
    Publication date: October 22, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles
  • Publication number: 20190092820
    Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: December 6, 2018
    Publication date: March 28, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Patent number: 10179805
    Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: January 15, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Publication number: 20190008949
    Abstract: The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Application
    Filed: September 12, 2018
    Publication date: January 10, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles
  • Patent number: 10098946
    Abstract: The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: October 16, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles
  • Publication number: 20170202947
    Abstract: The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 20, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles
  • Publication number: 20170107262
    Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 20, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Patent number: 9566327
    Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: February 14, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Publication number: 20160022805
    Abstract: Described herein is the generation of optimized H5N 1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 28, 2016
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Publication number: 20150030628
    Abstract: The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Application
    Filed: October 10, 2014
    Publication date: January 29, 2015
    Inventors: Ted M. Ross, Brendan M. Giles
  • Patent number: 8883171
    Abstract: Described herein is the development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: November 11, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles
  • Publication number: 20140127248
    Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: June 20, 2012
    Publication date: May 8, 2014
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Brendan M. Giles, Corey J. Crevar
  • Publication number: 20130183342
    Abstract: Described herein is the development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. It is disclosed herein that influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Application
    Filed: September 9, 2011
    Publication date: July 18, 2013
    Inventors: Ted M. Ross, Brendan M. Giles